BCAL Diagnostics is an Australian biotechnology company committed to the early, accurate diagnosis of breast cancer, and therefore early intervention and improved outcomes for women. Over the past decade, BCAL has developed a screening technology for the detection of breast cancer, with results to date demonstrating excellent performance independent of breast tissue density. Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange (ASX: BDX).